RETRACTION: Changes in the Expression of Melatonin Receptors Induced by Melatonin Treatment in Hepatocarcinoma HepG2 Cells(Journal of Pineal Research, (2009), 47, (330-338), 10.1111/j.1600-079X.2009.00719.x);Changes in the expression of melatonin receptors induced by melatonin treatment in hepatocarcinoma HepG2 cells

Journal of Pineal Research

Volumn 47, Issue 4, 2009, Pages 330-338

  Carbajo Pescador, Sara ^a   Martín Renedo, Javier ^a   García Palomo, Andrés ^b   Tuñón, María J ^a   Mauriz, José L ^a   González Gallego, Javier ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b Complejo Asistencial Universitario de León   (Spain)

Author keywords

Cell cycle; Hepatocarcinoma; Melatonin; Proliferation; Receptors

Indexed keywords

CELL NUCLEUS RECEPTOR; INDOLEAMINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN 3 RECEPTOR; MELATONIN RECEPTOR; PROTEIN P21; RETINOIC ACID; UNCLASSIFIED DRUG;

AGING; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 70350068403     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12975     Document Type: Erratum

References (63)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001 94 : 153 156. (Pubitemid 32911406)
2. Abou-Alfa GK, Venook AP. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep 2008 10 : 199 205.
3. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006 25 : 3866 3884.
4. Verslype C, Van Cutsem E, Dicato M et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009 20 (Suppl. 7 vii1 vii6.
5. Reiter RJ, Korkmaz A. Clinical aspects of melatonin. Saudi Med J 2008 29 : 1537 1547.
6. Korkmaz A, Reiter RJ, Topal T et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009 15 : 43 50.
7. Jan JE, Wasdell MB, Freeman RD, Bax M. Evidence supporting the use of melatonin in short gestation infants. J Pineal Res 2007 42 : 22 27.
8. Gitto E, Pellegrino S, Gitto P et al. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res 2009 46 : 128 139.
9. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008 44 : 26 40.
10. Tahan V, Atug O, Akin H et al. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. J Pineal Res 2009 46 : 401 407.
11. Liang R, Nickkholgh A, Hoffmann K et al. Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res 2009 46 : 8 14.
12. Mauriz JL, Molpeceres V, García-Mediavilla MV et al. Melatonin prevents oxidative stress and changes in antioxidant enzyme expression and activity in the liver of aging rats. J Pineal Res 2007 42 : 222 230.
13. Molpeceres V, Mauriz JL, García-Mediavilla MV et al. Melatonin is able to reduce the apoptotic liver changes induced by aging via inhibition of the intrinsic pathway of apoptosis. J Gerontol A Biol Sci Med Sci 2007 62 : 687 695.
14. Martín-Renedo J, Mauriz JL, Jorquera F et al. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008 45 : 532 540.
15. Carrillo-Vico A, Guerrero JM, Lardone PJ et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005 27 : 189 200.
16. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005 27 : 101 110.
17. Nosjean O, Ferro M, Coge F et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. Biochem Pharmacol 2001 61 : 1369 1379.
18. Pozo D, García-Mauriño S, Guerrero JM, Calvo JR. mRNA expression of nuclear receptor RZR/RORα, melatonin membrane receptor MT1 and hydroxindole-O-methyltransferase in different populations of human immune cells. J Pineal Res 2004 37 : 48 54.
19. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. J Inmunol Methods 1986 89 : 271 277.
20. Kucerová D, Sloncová E, Tuhácková Z et al. Expression and interaction of different catenins in colorectal carcinoma cells. Int J Mol Med 2001 8 : 695 698.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001 25 : 402 408.
22. Papazisis KT, Kouretas D, Geromichalos GD et al. Effects of melatonin on proliferation of cancer cell lines. J Pineal Res 1998 25 : 211 218.
23. Baldwin PJ, Bierman W, Jayadev J et al. The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res 1999 26 : 129 136.
24. Farriol M, Venereo Y, Orta X et al. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol 2000 20 : 21 24.
25. Anisimov VN, Popovich IG, Zabezhinski MA et al. Melatonin: antioxidant, genoprotector and anticarcinogen. Biochim Biophys Acta 2006 1757 : 573 589.
26. Hernández C, Abreu J, Abreu P et al. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J 2007 30 : 496 500.
27. Hill SM, Blask DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cell (MCF-7) in culture. Cancer Res 1988 48 : 6121 6126.
28. Shiu Syw, Li L, Xu JN et al. Melatonin-induced inhibition of proliferation and G1/S cell cycle, transition delay of human choriocarcinoma Jar cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 1999 27 : 183 192.
29. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003 22 : 9063 9074.
30. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004 337 : 1 13.
31. Atten MJ, Godoy-Romero E, Attar BM et al. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest New Drugs 2005 232 : 111 119.
32. García-Santos G, Antolín I, Herrera F et al. Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 2006 41 : 130 135.
33. Pandi-Perumal SR, Trakht I, Srinivasan V et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008 85 : 335 353.
34. Naji L, Carrillo-Vico A, Guerrero JM, Calvo JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004 74 : 2227 2236.
35. Aust S, Thalhammer T, Humpeler S et al. The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J Pineal Res 2004 36 : 43 48.
36. Ram PT, Dai J, Yuan L et al. Involvement of the MT1 melatonin receptor in human breast cancer. Cancer Lett 2002 179 : 141 150.
37. Slominski A, Fischer TW, Zmijewski MA et al. On the role of melatonin in skin physiology and pathology. Endocrine 2005 27 : 137 148.
38. Ekmekcioglu C, Haslmayer P, Philipp C et al. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res 2001 21 : 85 91.
39. Frungieri MB, Mayerhofer A, Zitta K et al. Direct effect of melatonin on Syrian hamster testes: melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local corticotropin-releasing hormone system. Endocrinology 2005 146 : 1541 1552.
40. Clemens JW, Jarzynka MJ, Witt-Enderby PA. Down-regulation of MT1 melatonin receptors in rat ovary following estrogen exposure. Life Sci 2001 69 : 27 35.
41. Akiyoshi J, Hough C, Chuang DM. Paradoxical increase of 5-hydroxytryptamine2 receptors and 5-hydroxytryptamine2 receptor mRNA in cerebellar granule cells after persistent 5-hydroxytryptamine2 receptor stimulation. Mol Pharmacol 1993 43 : 349 355.
42. Thomas RF, Holt BD, Schwinn DA, Liggett SB. Long-term agonist exposure induces upregulation of beta 3-adrenergic receptor expression via multiple cAMP response elements. Proc Natl Acad Sci USA 1992 89 : 4490 4494.
43. Starr S, Kozell LB, Neve KA. Drug-induced up-regulation of dopamine D2 receptors on cultured cells. J Neurochem 1995 65 : 569 577.
44. Filtz TM, Artymyshyn RP, Guan W, Molinoff PB. Paradoxical regulation of dopamine receptors in transfected 293 cells. Mol Pharmacol 1993 44 : 371 379.
45. Yuan L, Collins AR, Dai J et al. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 2002 192 : 147 156.
46. Toma CD, Svoboda M, Arrich F et al. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors. J Pineal Res 2007 43 : 206 213. (Pubitemid 47077224)
47. Masana MI, Witt-Enderby PA, Dubocovich ML. Melatonin differentially modulates the expression and function of the hMT1 and hMT2 melatonin receptors upon prolonged withdrawal. Biochem Pharmacol 2003 65 : 731 739.
48. Chan AS, Lai FP, Lo RK et al. Melatonin MT1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal 2002 14 : 249 257.
49. Kobayashi Y, Itoh MT, Kondo H et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res 2003 35 : 71 74.
50. Maillet F, Ferry G, Vella F et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase2 enzyme. Biochem Pharmacol 2005 71 : 74 88.
51. Tan DX, Manchester LC, Terron MP et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 2007 43 : 317 320.
52. Pintor J, Pelaez T, Hoyle CH, Peral A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol 2003 138 : 831 836.
53. Iskander K, Paquet M, Brayton C, Jaiswal AK. Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis. Cancer Res 2004 64 : 5925 5928.
54. Hsieh TC, Wang Z, Hamby CV, Wu JM. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem Biophys Res Commun 2005 334 : 223 230.
55. Fischer TW, Zmijewski MA, Zbytek B et al. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol 2006 29 : 665 672.
56. Carlberg C, Hooft van Huijsduijnen R, Staple JK et al. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol Endocrinol 1994 8 : 757 770.
57. Kang HS, Angers M, Beak JY et al. Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics 2007 31 : 281 294.
58. Chauvet C, Bois-Joyeux B, Berra E et al. The gene encoding human retinoic acid-receptor-related orphan receptor alpha is a target for hypoxia-inducible factor 1. Biochem J 2004 384 : 79 85.
59. Chen Y, Coulter S, Jetten AM, Goldstein JA. Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene. J Pharmacol Exp Ther 2009 329 : 192 201.
60. Wiesenberg I, Missbach M, Kahlen JP et al. Transcriptional activation of the nuclear receptor RZR alpha by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 1995 23 : 327 333.
61. Karasek M, Gruszka A, Lawnicka H et al. Melatonin inhibits growth of diethylstilbestrol-induced prolactin-secreting pituitary tumor in vitro: possible involvement of nuclear RZR/ROR receptors. J Pineal Res 2003 34 : 294 296.
62. Schräder M, Danielsson C, Wiesenberg I, Carlberg C. Identification of natural monomeric response elements of the nuclear receptor RZR/ROR. They also bind COUP-TF homodimers. J Biol Chem 1996 271 : 19732 19736.
63. Gong Y, Deng S, Zhang M et al. A cyclin-dependent kinase inhibitor (p21(WAF1/CIP1)) affects thymidine incorporation in human liver cancer cells. Br J Cancer 2002 86 : 625 629.